Form 4: ProMIS CEO Neil Warma Granted 600,000 Stock Options

ProMIS Neurosciences Inc. CEO Neil Warma was granted 600,000 stock options with an exercise price of $0.45, vesting over time.

Summary

• Neil K. Warma, Chief Executive Officer and Director of ProMIS Neurosciences Inc. (PMN), acquired 600,000 derivative securities in the form of stock options.
• The transaction date for this grant was September 22, 2025.
• Each option has an exercise price of $0.45.
• The options will vest with 25% of the shares subject to the option vesting on September 1, 2026, and the remaining balance vesting ratably over 36 months thereafter.
• The expiration date for these options is September 22, 2035.
• Following this reported transaction, Neil K. Warma beneficially owns 600,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The grant of stock options to the CEO is generally a positive signal, indicating alignment of management and shareholder interests and providing an incentive for long-term performance. It is a standard compensation practice.

Positives

• The grant of stock options to the CEO aligns management's interests with those of shareholders, incentivizing long-term performance and share price appreciation.
• The vesting schedule encourages long-term commitment from the CEO to the company's success.

Future Outlook

The vesting schedule for the granted options indicates a long-term commitment from the CEO, with a significant portion of the options vesting over a 36-month period following an initial 25% vesting in September 2026.

Industry Context

The grant of stock options to a Chief Executive Officer is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive compensation packages designed to attract, retain, and motivate top talent by linking their financial incentives to company performance and shareholder value creation.

Comparison to Industry Standards

• Executive stock option grants are a standard component of compensation for CEOs in the biotech sector, comparable to practices at companies like Biogen Inc. or Eli Lilly and Company, though the specific size and exercise price are tailored to the company's stage and market capitalization.
• The vesting schedule, with an initial cliff and subsequent ratable vesting, is typical for long-term incentive plans across the industry, aiming to ensure sustained executive commitment.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also increased alignment of CEO's financial interests with shareholder value creation.

Next Steps

• The options will begin to vest, with 25% becoming exercisable on September 1, 2026.
• The remaining options will vest ratably over the subsequent 36 months.

Key Dates

Keywords

ProMIS Neurosciences, PMN, Neil Warma, stock options, CEO, insider transaction, executive compensation, Form 4